The stock of Seres Therapeutics Inc (MCRB) has seen a 13.54% increase in the past week, with a -19.98% drop in the past month, and a -22.94% decrease in the past quarter. The volatility ratio for the week is 14.25%, and the volatility levels for the past 30 days are at 8.97% for MCRB. The simple moving average for the past 20 days is -11.13% for MCRB’s stock, with a -31.08% simple moving average for the past 200 days.
Is It Worth Investing in Seres Therapeutics Inc (NASDAQ: MCRB) Right Now?
Additionally, the 36-month beta value for MCRB is 2.83. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for MCRB is 127.46M and currently, short sellers hold a 12.56% ratio of that float. The average trading volume of MCRB on April 15, 2025 was 1.26M shares.
MCRB) stock’s latest price update
Seres Therapeutics Inc (NASDAQ: MCRB) has experienced a decline in its stock price by -10.98 compared to its previous closing price of 0.66. However, the company has seen a gain of 13.54% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-13 that Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Carlo Tanzi – Kendall Investor Relations Eric Shaff – President and Chief Executive Officer Lisa von Moltke – Executive Vice President and Chief Medical Officer Matthew Henn – Executive Vice President and Chief Scientific Officer Terri Young – Executive Vice President, Chief Commercial and Strategy Officer Marella Thorell – Executive Vice President and Chief Financial Officer Chris McChalicher – Senior Vice President, Manufacturing, Quality and Process Development Conference Call Participants Joseph Thome – TD Cowen Caroline Pocher – JPMorgan Edward Tenthoff – Piper Sandler John Newman – Canaccord Genuity Operator Thank you for standing by. My name is Kate, and I will be your conference operator today.
Analysts’ Opinion of MCRB
Oppenheimer, on the other hand, stated in their research note that they expect to see MCRB reach a price target of $12. The rating they have provided for MCRB stocks is “Outperform” according to the report published on June 26th, 2023.
JP Morgan gave a rating of “Neutral” to MCRB, setting the target price at $7 in the report published on April 21st of the previous year.
MCRB Trading at -18.52% from the 50-Day Moving Average
After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.41% of loss for the given period.
Volatility was left at 8.97%, however, over the last 30 days, the volatility rate increased by 14.25%, as shares sank -20.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.94% lower at present.
During the last 5 trading sessions, MCRB rose by +13.52%, which changed the moving average for the period of 200-days by -24.80% in comparison to the 20-day moving average, which settled at $0.6643. In addition, Seres Therapeutics Inc saw -28.94% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MCRB starting from Young Teresa L., who sale 3,338 shares at the price of $0.81 back on Feb 18 ’25. After this action, Young Teresa L. now owns 97,536 shares of Seres Therapeutics Inc, valued at $2,704 using the latest closing price.
Henn Matthew R., the of Seres Therapeutics Inc, sale 3,953 shares at $0.81 during a trade that took place back on Feb 18 ’25, which means that Henn Matthew R. is holding 84,443 shares at $3,204 based on the most recent closing price.
Stock Fundamentals for MCRB
The total capital return value is set at -1.28. Equity return is now at value -3758.21, with -56.05 for asset returns.
Based on Seres Therapeutics Inc (MCRB), the company’s capital structure generated 0.87 points at debt to capital in total, while cash flow to debt ratio is standing at -1.62. The debt to equity ratio resting at 6.65. The interest coverage ratio of the stock is -15.6.
Currently, EBITDA for the company is -121.31 million with net debt to EBITDA at -0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.94.
Conclusion
In conclusion, Seres Therapeutics Inc (MCRB) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
